Heron Therapeutics, Inc. (HRTX) Q2 2026 Earnings Call Transcript

10.08.2026

Heron Therapeutics (HRTX) Reports Q2 Loss, Lags Revenue Estimates

Heron Therapeutics (HRTX) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.02 per share a year ago.

10.08.2026

Heron Therapeutics Q2 Earnings Call Highlights

Heron Therapeutics NASDAQ: HRTX reported second-quarter net revenue of $37.7 million, up from $34.7 million in the first quarter and $37.2 million in the comparable prior-year period, while management said sales of its key products came in below its internal expectations.

Videos

No Data

There is no data to display

Upgrades / Downgrades

Ticker	Brokerage Firm	Ratings Change	Price Target	Date
HRTX	H.C. Wainwright	Neutral	undefined >> undefined	August 11th 2026

Heron Therapeutics, Inc. (HRTX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Heron Therapeutics, Inc. (HRTX)

Heron Therapeutics, Inc. (HRTX) Q2 2026 Earnings Call Transcript

Heron Therapeutics (HRTX) Reports Q2 Loss, Lags Revenue Estimates

Heron Therapeutics Q2 Earnings Call Highlights

Videos

No Data

Upgrades / Downgrades

Search stocks

Heron Therapeutics, Inc. (HRTX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Heron Therapeutics, Inc. (HRTX)

Heron Therapeutics, Inc. (HRTX) Q2 2026 Earnings Call Transcript

Heron Therapeutics (HRTX) Reports Q2 Loss, Lags Revenue Estimates

Heron Therapeutics Q2 Earnings Call Highlights

Videos

No Data

Upgrades / Downgrades